Cargando…
The Efficacy of HGF/VEGF Gene Therapy for Limb Ischemia in Mice with Impaired Glucose Tolerance: Shift from Angiogenesis to Axonal Growth and Oxidative Potential in Skeletal Muscle
Background: Combined non-viral gene therapy (GT) of ischemia and cardiovascular disease is a promising tool for potential clinical translation. In previous studies our group has developed combined gene therapy by vascular endothelial growth factor 165 (VEGF165) + hepatocyte growth factor (HGF). Our...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9737863/ https://www.ncbi.nlm.nih.gov/pubmed/36497083 http://dx.doi.org/10.3390/cells11233824 |
_version_ | 1784847394335096832 |
---|---|
author | Stafeev I, Iurii S. Boldyreva, Maria A. Michurina, Svetlana S. Agareva, Margarita Yu. Radnaeva, Arina V. Menshikov, Mikhail Yu. Hu, Yu-Chen Makarevich, Pavel I. Parfyonova, Yelena V. |
author_facet | Stafeev I, Iurii S. Boldyreva, Maria A. Michurina, Svetlana S. Agareva, Margarita Yu. Radnaeva, Arina V. Menshikov, Mikhail Yu. Hu, Yu-Chen Makarevich, Pavel I. Parfyonova, Yelena V. |
author_sort | Stafeev I, Iurii S. |
collection | PubMed |
description | Background: Combined non-viral gene therapy (GT) of ischemia and cardiovascular disease is a promising tool for potential clinical translation. In previous studies our group has developed combined gene therapy by vascular endothelial growth factor 165 (VEGF165) + hepatocyte growth factor (HGF). Our recent works have demonstrated that a bicistronic pDNA that carries both human HGF and VEGF165 coding sequences has a potential for clinical application in peripheral artery disease (PAD). The present study aimed to test HGF/VEGF combined plasmid efficacy in ischemic skeletal muscle comorbid with predominant complications of PAD-impaired glucose tolerance and type 2 diabetes mellitus (T2DM). Methods: Male C57BL mice were housed on low-fat (LFD) or high-fat diet (HFD) for 10 weeks and metabolic parameters including FBG level, ITT, and GTT were evaluated. Hindlimb ischemia induction and plasmid administration were performed at 10 weeks with 3 weeks for post-surgical follow-up. Limb blood flow was assessed by laser Doppler scanning at 7, 14, and 21 days after ischemia induction. The necrotic area of m.tibialis anterior, macrophage infiltration, angio- and neuritogenesis were evaluated in tissue sections. The mitochondrial status of skeletal muscle (total mitochondria content, ETC proteins content) was assessed by Western blotting of muscle lysates. Results: At 10 weeks, the HFD group demonstrated impaired glucose tolerance in comparison with the LFD group. HGF/VEGF plasmid injection aggravated glucose intolerance in HFD conditions. Blood flow recovery was not changed by HGF/VEGF plasmid injection either in LFD or HFD conditions. GT in LFD, but not in HFD conditions, enlarged the necrotic area and CD68+ cells infiltration. However, HGF/VEGF plasmid enhanced neuritogenesis and enlarged NF200+ area on muscle sections. In HFD conditions, HGF/VEGF plasmid injection significantly increased mitochondria content and ETC proteins content. Conclusions: The current study demonstrated a significant role of dietary conditions in pre-clinical testing of non-viral GT drugs. HGF/VEGF combined plasmid demonstrated a novel aspect of potential participation in ischemic skeletal muscle regeneration, through regulation of innervation and bioenergetics of muscle. The obtained results made HGF/VEGF combined plasmid a very promising tool for PAD therapy in impaired glucose tolerance conditions. |
format | Online Article Text |
id | pubmed-9737863 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-97378632022-12-11 The Efficacy of HGF/VEGF Gene Therapy for Limb Ischemia in Mice with Impaired Glucose Tolerance: Shift from Angiogenesis to Axonal Growth and Oxidative Potential in Skeletal Muscle Stafeev I, Iurii S. Boldyreva, Maria A. Michurina, Svetlana S. Agareva, Margarita Yu. Radnaeva, Arina V. Menshikov, Mikhail Yu. Hu, Yu-Chen Makarevich, Pavel I. Parfyonova, Yelena V. Cells Article Background: Combined non-viral gene therapy (GT) of ischemia and cardiovascular disease is a promising tool for potential clinical translation. In previous studies our group has developed combined gene therapy by vascular endothelial growth factor 165 (VEGF165) + hepatocyte growth factor (HGF). Our recent works have demonstrated that a bicistronic pDNA that carries both human HGF and VEGF165 coding sequences has a potential for clinical application in peripheral artery disease (PAD). The present study aimed to test HGF/VEGF combined plasmid efficacy in ischemic skeletal muscle comorbid with predominant complications of PAD-impaired glucose tolerance and type 2 diabetes mellitus (T2DM). Methods: Male C57BL mice were housed on low-fat (LFD) or high-fat diet (HFD) for 10 weeks and metabolic parameters including FBG level, ITT, and GTT were evaluated. Hindlimb ischemia induction and plasmid administration were performed at 10 weeks with 3 weeks for post-surgical follow-up. Limb blood flow was assessed by laser Doppler scanning at 7, 14, and 21 days after ischemia induction. The necrotic area of m.tibialis anterior, macrophage infiltration, angio- and neuritogenesis were evaluated in tissue sections. The mitochondrial status of skeletal muscle (total mitochondria content, ETC proteins content) was assessed by Western blotting of muscle lysates. Results: At 10 weeks, the HFD group demonstrated impaired glucose tolerance in comparison with the LFD group. HGF/VEGF plasmid injection aggravated glucose intolerance in HFD conditions. Blood flow recovery was not changed by HGF/VEGF plasmid injection either in LFD or HFD conditions. GT in LFD, but not in HFD conditions, enlarged the necrotic area and CD68+ cells infiltration. However, HGF/VEGF plasmid enhanced neuritogenesis and enlarged NF200+ area on muscle sections. In HFD conditions, HGF/VEGF plasmid injection significantly increased mitochondria content and ETC proteins content. Conclusions: The current study demonstrated a significant role of dietary conditions in pre-clinical testing of non-viral GT drugs. HGF/VEGF combined plasmid demonstrated a novel aspect of potential participation in ischemic skeletal muscle regeneration, through regulation of innervation and bioenergetics of muscle. The obtained results made HGF/VEGF combined plasmid a very promising tool for PAD therapy in impaired glucose tolerance conditions. MDPI 2022-11-29 /pmc/articles/PMC9737863/ /pubmed/36497083 http://dx.doi.org/10.3390/cells11233824 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Stafeev I, Iurii S. Boldyreva, Maria A. Michurina, Svetlana S. Agareva, Margarita Yu. Radnaeva, Arina V. Menshikov, Mikhail Yu. Hu, Yu-Chen Makarevich, Pavel I. Parfyonova, Yelena V. The Efficacy of HGF/VEGF Gene Therapy for Limb Ischemia in Mice with Impaired Glucose Tolerance: Shift from Angiogenesis to Axonal Growth and Oxidative Potential in Skeletal Muscle |
title | The Efficacy of HGF/VEGF Gene Therapy for Limb Ischemia in Mice with Impaired Glucose Tolerance: Shift from Angiogenesis to Axonal Growth and Oxidative Potential in Skeletal Muscle |
title_full | The Efficacy of HGF/VEGF Gene Therapy for Limb Ischemia in Mice with Impaired Glucose Tolerance: Shift from Angiogenesis to Axonal Growth and Oxidative Potential in Skeletal Muscle |
title_fullStr | The Efficacy of HGF/VEGF Gene Therapy for Limb Ischemia in Mice with Impaired Glucose Tolerance: Shift from Angiogenesis to Axonal Growth and Oxidative Potential in Skeletal Muscle |
title_full_unstemmed | The Efficacy of HGF/VEGF Gene Therapy for Limb Ischemia in Mice with Impaired Glucose Tolerance: Shift from Angiogenesis to Axonal Growth and Oxidative Potential in Skeletal Muscle |
title_short | The Efficacy of HGF/VEGF Gene Therapy for Limb Ischemia in Mice with Impaired Glucose Tolerance: Shift from Angiogenesis to Axonal Growth and Oxidative Potential in Skeletal Muscle |
title_sort | efficacy of hgf/vegf gene therapy for limb ischemia in mice with impaired glucose tolerance: shift from angiogenesis to axonal growth and oxidative potential in skeletal muscle |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9737863/ https://www.ncbi.nlm.nih.gov/pubmed/36497083 http://dx.doi.org/10.3390/cells11233824 |
work_keys_str_mv | AT stafeeviiuriis theefficacyofhgfvegfgenetherapyforlimbischemiainmicewithimpairedglucosetoleranceshiftfromangiogenesistoaxonalgrowthandoxidativepotentialinskeletalmuscle AT boldyrevamariaa theefficacyofhgfvegfgenetherapyforlimbischemiainmicewithimpairedglucosetoleranceshiftfromangiogenesistoaxonalgrowthandoxidativepotentialinskeletalmuscle AT michurinasvetlanas theefficacyofhgfvegfgenetherapyforlimbischemiainmicewithimpairedglucosetoleranceshiftfromangiogenesistoaxonalgrowthandoxidativepotentialinskeletalmuscle AT agarevamargaritayu theefficacyofhgfvegfgenetherapyforlimbischemiainmicewithimpairedglucosetoleranceshiftfromangiogenesistoaxonalgrowthandoxidativepotentialinskeletalmuscle AT radnaevaarinav theefficacyofhgfvegfgenetherapyforlimbischemiainmicewithimpairedglucosetoleranceshiftfromangiogenesistoaxonalgrowthandoxidativepotentialinskeletalmuscle AT menshikovmikhailyu theefficacyofhgfvegfgenetherapyforlimbischemiainmicewithimpairedglucosetoleranceshiftfromangiogenesistoaxonalgrowthandoxidativepotentialinskeletalmuscle AT huyuchen theefficacyofhgfvegfgenetherapyforlimbischemiainmicewithimpairedglucosetoleranceshiftfromangiogenesistoaxonalgrowthandoxidativepotentialinskeletalmuscle AT makarevichpaveli theefficacyofhgfvegfgenetherapyforlimbischemiainmicewithimpairedglucosetoleranceshiftfromangiogenesistoaxonalgrowthandoxidativepotentialinskeletalmuscle AT parfyonovayelenav theefficacyofhgfvegfgenetherapyforlimbischemiainmicewithimpairedglucosetoleranceshiftfromangiogenesistoaxonalgrowthandoxidativepotentialinskeletalmuscle AT stafeeviiuriis efficacyofhgfvegfgenetherapyforlimbischemiainmicewithimpairedglucosetoleranceshiftfromangiogenesistoaxonalgrowthandoxidativepotentialinskeletalmuscle AT boldyrevamariaa efficacyofhgfvegfgenetherapyforlimbischemiainmicewithimpairedglucosetoleranceshiftfromangiogenesistoaxonalgrowthandoxidativepotentialinskeletalmuscle AT michurinasvetlanas efficacyofhgfvegfgenetherapyforlimbischemiainmicewithimpairedglucosetoleranceshiftfromangiogenesistoaxonalgrowthandoxidativepotentialinskeletalmuscle AT agarevamargaritayu efficacyofhgfvegfgenetherapyforlimbischemiainmicewithimpairedglucosetoleranceshiftfromangiogenesistoaxonalgrowthandoxidativepotentialinskeletalmuscle AT radnaevaarinav efficacyofhgfvegfgenetherapyforlimbischemiainmicewithimpairedglucosetoleranceshiftfromangiogenesistoaxonalgrowthandoxidativepotentialinskeletalmuscle AT menshikovmikhailyu efficacyofhgfvegfgenetherapyforlimbischemiainmicewithimpairedglucosetoleranceshiftfromangiogenesistoaxonalgrowthandoxidativepotentialinskeletalmuscle AT huyuchen efficacyofhgfvegfgenetherapyforlimbischemiainmicewithimpairedglucosetoleranceshiftfromangiogenesistoaxonalgrowthandoxidativepotentialinskeletalmuscle AT makarevichpaveli efficacyofhgfvegfgenetherapyforlimbischemiainmicewithimpairedglucosetoleranceshiftfromangiogenesistoaxonalgrowthandoxidativepotentialinskeletalmuscle AT parfyonovayelenav efficacyofhgfvegfgenetherapyforlimbischemiainmicewithimpairedglucosetoleranceshiftfromangiogenesistoaxonalgrowthandoxidativepotentialinskeletalmuscle |